TY - JOUR
T1 - Effect of atorvastatin to RANKL/OPG system in patients with acute coronary syndrome
AU - Pérez-Castrillon, J. L.
AU - Abad, L.
AU - Vega, G.
AU - Sanz-Cantalapiedra, A.
AU - San Miguel, A.
AU - Mazón, A.
AU - Sanchez, S.
AU - Hernandez, G.
AU - Dueñas-Laita, A.
PY - 2005
Y1 - 2005
N2 - Background: The prominent effect of statin therapy is the inhibition of hydroxymethyl glutaryl-Coenzyme A (HMG-CoA) reductase. This enzyme decreases the mevalonate level and prevents the synthesis of isoprenoids. This inhibition alters osteoclast activity. Osteoprotegerin (OPG) acts as a decoy receptor of the receptor activator of nuclear factor kB (NF-kB) ligand (RANKL), which is a key regulator of osteoclastogenesis. Objective: The aim of this study is to evaluate the effect of atorvastatin on the RANKL/OPG system in patients with acute coronary syndrome. Material and Methods: We studied 22 patients (17 men and 5 women, age 61 ± 8 years) referred to Hospital Rio Hortega with a diagnosis of acute coronary syndrome. The following parameters were determined: osteocalcin, paratohormone, 25-vitamin D, RANKL, and osteoprotegerin. Deoxypiridinoline was determined in urine samples. The same parameters were determined after 12 months. The patients were treated with atorvastatin. Results: Atorvastatin resulted in plasmatic level decreases of osteocalcin (3.8 ± 2 pmol/L vs 2 ± 1 pmol/L; P=0.022), RANKL (0.17 ± 0.13 vs 0.01 ± 0.02; P=0.02), and RANKL/OPG (0.02 ± 0.02; P=0.04). Conclusions: Atorvastatin decreases RANKL and osteocalcin levels in patients with acute myocardial infarction. Atorvastatin may increase the bone mineral density by inhibing the resorption through RANKL/OPG system.
AB - Background: The prominent effect of statin therapy is the inhibition of hydroxymethyl glutaryl-Coenzyme A (HMG-CoA) reductase. This enzyme decreases the mevalonate level and prevents the synthesis of isoprenoids. This inhibition alters osteoclast activity. Osteoprotegerin (OPG) acts as a decoy receptor of the receptor activator of nuclear factor kB (NF-kB) ligand (RANKL), which is a key regulator of osteoclastogenesis. Objective: The aim of this study is to evaluate the effect of atorvastatin on the RANKL/OPG system in patients with acute coronary syndrome. Material and Methods: We studied 22 patients (17 men and 5 women, age 61 ± 8 years) referred to Hospital Rio Hortega with a diagnosis of acute coronary syndrome. The following parameters were determined: osteocalcin, paratohormone, 25-vitamin D, RANKL, and osteoprotegerin. Deoxypiridinoline was determined in urine samples. The same parameters were determined after 12 months. The patients were treated with atorvastatin. Results: Atorvastatin resulted in plasmatic level decreases of osteocalcin (3.8 ± 2 pmol/L vs 2 ± 1 pmol/L; P=0.022), RANKL (0.17 ± 0.13 vs 0.01 ± 0.02; P=0.02), and RANKL/OPG (0.02 ± 0.02; P=0.04). Conclusions: Atorvastatin decreases RANKL and osteocalcin levels in patients with acute myocardial infarction. Atorvastatin may increase the bone mineral density by inhibing the resorption through RANKL/OPG system.
KW - Atorvastatin
KW - Osteoprotegerin
KW - RANKL
UR - https://www.scopus.com/pages/publications/33750837686
M3 - Article
AN - SCOPUS:33750837686
SN - 1537-064X
VL - 5
SP - 569
EP - 574
JO - Journal of Applied Research
JF - Journal of Applied Research
IS - 4
ER -